Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction

Robert L. Levine, Marcie J. Hursting, David McCollum

Research output: Contribution to journalArticlepeer-review

74 Scopus citations

Abstract

Study objectives: We evaluated the dosing requirements in argatroban-treated patients with heparin-induced thrombocytopenia (HIT) and hepatic dysfunction, and compared efficacy and safely outcomes with historical control patients. Design: Retrospective analysis. Setting: Inpatient setting. Patients: Patients with hepatic dysfunction, defined as total bilirubin > 25.5 μmol/L (1.5 mg/dL), aspartate aminotransferase >100 IU/L, and/or alanine aminotransferase > 100 IU/L, were identified from previous multicenter, historical-controlled studies of argatoroban therapy in HIT. Interventions: Argatroban, adjusted to maintain activated partial thromboplastin times (aPTTs) 1.5 to 3 times baseline in the experimental group, vs no direct thrombin inhibition in the historical control patients. Measurements and results: The analysis population included 82 argatroban patients and 34 historical control patients with hepatic impairment, of whom approximately 50% in each group had renal dysfunction (defined as a serum creatinine level > 1.3 mg/dL). The argatroban dosage was 1.6 ± 1.1 μg/kg/min (mean ± SD) over a mean 5-day course of therapy. Significantly lower doses were used in patients with elevated vs normal total bilirubin levels (0.8 ± 0.6 μg/kg/min vs 1.7 ± 0.8 μg/kg/min, p = 0.0063) and in patients with hepatic/renal dysfunction vs hepatic dysfunction alone (1.2 ± 1.1 μg/kg/min vs 2.0 ± 1.1 μg/kg/min, p < 0.001). The aPTT 24 h after argatroban initiation was 69 ± 22 s, with 80% of patients having a therapeutic level of anlicoagulation. Thirty-four argatroban-treated patients (41.5%) and 17 control patients (50.0%) experienced the 37-day composite end point of death, amputation, or new thrombosis (p = 0.32). Argatroban significantly reduced new thrombosis (8.5% vs 26.5%, p = 0.012). Major bleeding was similar between treatment groups (4.9% vs 2.9%, p = 0.684). Conclusions: Hepatic dysfunction affects argatroban dosing, with reduced doses required particularly in patients with serum total bilirubin levels > 25.5 μmol/L (1.5 mg/dL) or combined hepatic/renal dysfunction. Individual mean aPTT-adjusted doses typically remain ≥ 0.5 μg/kg/min, supporting the recommendation of 0.5 μg/kg/min as a conservative initial dose for most patients with hepatic impairment. Argatroban, with proper initial dosing and monitoring, can provide safe and effective antithrombotic therapy in patients with HIT and hepatic impairment.

Original languageEnglish (US)
Pages (from-to)1167-1175
Number of pages9
JournalCHEST
Volume129
Issue number5
DOIs
StatePublished - May 2006

Keywords

  • Anticoagulants
  • Heparin
  • Hepatic dysfunction
  • Renal dysfunction
  • Thrombocytopenia
  • Thrombosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction'. Together they form a unique fingerprint.

Cite this